New data from REDUCE LAP-HF clinical study of its InterAtrial Shunt Device in heart failure- Corvia Medical

Corvia Medical announced one-year follow-up data from the REDUCE LAP-HF clinical study of its InterAtrial Shunt Device (IASD). The IASD is the world's first transcatheter device designed to treat heart failure with preserved ejection fraction (HFpEF), previously called diastolic heart failure. The results of the ongoing 64-patient study confirm a good safety profile, sustained device performance (blood flow from the left to right atrium) and clinically meaningful patient-focused outcomes including fewer heart failure symptoms, the ability to exercise longer, and a substantially improved quality of life.

Highlights include a median New York Heart Association (NYHA) functional class improved from 3 to 2, plus a mean quality of life score (Minnesota Living with Heart Failure questionnaire) improved 15 points from 49 to 34. In addition, a mean 6-minute walk distance improved over 30 meters, from 331 meters to 363 meters. Data was presented in the late-breaking sessions at the American Heart Association Scientific Sessions 2016.